Key Points
-
The disposition involved 11,650 shares at a weighted average price of $235.72, totaling approximately $2.7 million.
-
Greene executed the sale directly and maintains no indirect equity holdings through trusts or other legal entities.
-
The activity occurred following a period of appreciation for the company, with shares reflecting a 57% one-year return as of the August 18 transaction date.
- 10 stocks we like better than Cardinal Health ›
Michelle D. Greene, chief information officer of Cardinal Health, Inc. (NYSE:CAH), sold 11,650 shares of common stock on August 18, according to a recent SEC Form 4 filing.
Transaction summary
MetricValueShares sold (directly held)11,650Transaction value$2.7 millionPost-transaction shares (directly held)10,330Post-transaction value$2.43 million
Transaction value based on SEC Form 4 weighted average sale price ($235.72); post-transaction value based on the August 18 market close ($234.98).
Key questions
- How was the price execution structured for this disposition?The shares were sold in multiple transactions at prices ranging from $234.07 to $237.32 per share, resulting in the reported weighted average of $235.72.
- What is the current scale of the company’s market position?The company is a global provider of healthcare services and products, with a market capitalization of $55.0 billion and a workforce of 58,788 employees as of the August 19 market close.
- What does the insider’s remaining equity exposure look like?Following this sale, Greene retains direct ownership of 10,330 shares.
- What are the primary segments driving the company’s financial results?The company is organized into Pharmaceutical and Medical divisions, which collectively generated trailing-twelve-month revenue of $254.2 billion and net income of $1.7 billion.
Company Overview
MetricValueShare Price (as of market close 2026-08-19)$234.85Market Capitalization$55.0 billionRevenue (TTM)$254.2 billionNet Income (TTM)$1.7 billion
Company Snapshot
- Cardinal Health operates as a global, integrated healthcare services and products provider, delivering pharmaceutical distribution, medical supplies, and healthcare solutions across the United States, Canada, Europe, Asia, and international markets.
- The company generates revenue through its two core operating divisions–Pharmaceutical and Medical–which provide distribution, logistics, and specialized healthcare services to institutional and individual customers.
- Cardinal Health serves a diverse customer base, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical laboratories, physician practices, and patients receiving home-based care.
Cardinal Health is one of the largest healthcare services and products companies globally, with TTM revenue of $254.2 billion. The company maintains a competitive position through its integrated distribution network, broad customer relationships, and diversified service offerings across pharmaceutical and medical segments. Cardinal Health’s scale and operational infrastructure enable it to serve as a critical intermediary within the healthcare supply chain, supporting healthcare providers and patients across multiple geographies and care settings.
What this transaction means for investors
Greene finished Cardinal’s August award cycle holding less stock than she went into it with. She had 12,230 shares before performance units landed on Aug. 4 and 10,330 after the selling stopped, a cut of roughly 16%. CEO Jason Hollar and chief legal officer Jessica Mayer sold in the same window and both finished within about 5% of where they started, so Greene went meaningfully deeper, though not as deep as CFO Aaron Alt.
Meanwhile, her role maps onto what management spent the Aug. 11 earnings call selling. Cardinal’s chief information officer runs the automation and technology budget that Hollar credited for record service levels and order accuracy, and the spending is real. Capital expenditures hit $649 million in fiscal 2026 and are expected to step up to roughly $700 million this year. Alt told analysts the company is “executing on a multiyear investment plan.” Meanwhile adjusted free cash flow is guided to $3.5 billion to $4 billion for fiscal 2027, down from the $5 billion it just posted. Alt chalked it up to business growth, working capital discipline and cash-focused initiatives, which are reasons the number should climb rather than drop by more than a billion. Long-term investors should keep an eye on how that number eoles.
Should you buy stock in Cardinal Health right now?
Before you buy stock in Cardinal Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cardinal Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $429,223!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,318,055!*
Now, it’s worth noting Stock Advisor’s total average return is 965% — a market-crushing outperformance compared to 212% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
